Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001034 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 850
- Enrollment target
NCT00001034: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001034 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 850 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (539% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001034, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 850 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected patients with severe immunosuppression. The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until recently, both drugs required intravenous administration. An oral form of ganciclovir, if shown to be effective therapy against CMV, would be a more suitable method of administration for prophylaxis.
Interventions
- DRUG Ganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Est. Completion | 1995-08 |
| Phase | Phase 2 |
What the finished NCT00001034 record still lists
NCT00001034 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (539% higher).
The record links to 0 conditions, and to 1 intervention - of which Ganciclovir is the first listed.
NCT00001034 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001034 about?
NCT00001034 is a clinical study titled "The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV". To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected patients with severe immunosuppression. The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until recent...
What is the current status of trial NCT00001034?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 850 participants. Estimated completion is 1995-08.
What interventions are being tested in trial NCT00001034?
The interventions under investigation include: Ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00001034?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00001034's enrollment target sits among peer trials
850 35th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma